GKWIM
ALLO icon

Gerber Kawasaki Wealth & Investment Management’s Allogene Therapeutics ALLO Stock Holding History

Gerber Kawasaki Wealth & Investment Management’s Portfolio ALLO Stock Details ALLO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-10
Closed – – 308
2021
Q3 		$0 Buy
+10
New +$237 ﹤0.01% 1167

Other funds holding ALLO

TGA
TPG GP A Fort Worth, Texas $3.68B AUM 14.99% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Gerber Kawasaki Wealth & Investment Management's ALLO Position: Q4 2021 in Review

Gerber Kawasaki Wealth & Investment Management sold out of Allogene Therapeutics (ALLO) in Q4 2021, closing a stake of 10 shares.

Gerber Kawasaki Wealth & Investment Management first reported a position in ALLO in Q3 2021 and held it in 1 quarter. The position peaked at $0 in Q3 2021. 177 funds tracked by Wall St. Rank hold ALLO as of Q4 2021.

  • Gerber Kawasaki Wealth & Investment Management reported no remaining Allogene Therapeutics position as of Q4 2021 after selling out during the quarter.
  • Gerber Kawasaki Wealth & Investment Management sold 10 Allogene Therapeutics shares in Q4 2021.
  • Gerber Kawasaki Wealth & Investment Management first reported a position in Allogene Therapeutics in Q3 2021 and held it in 1 quarter.
  • Gerber Kawasaki Wealth & Investment Management's Allogene Therapeutics position peaked at $0 in Q3 2021.
  • 177 funds tracked by Wall St. Rank held Allogene Therapeutics as of Q4 2021.

Based on Gerber Kawasaki Wealth & Investment Management's 13F filing for Q4 2021, filed 11 Feb 2022.